Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common anesthetic gas help ARDS patients breathe easier?

NCT ID NCT02166853

Disease control Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether inhaling sevoflurane, a gas usually used for anesthesia, for the first 48 hours could improve oxygen levels and reduce inflammation in 50 adults with moderate to severe ARDS. Participants were randomly assigned to receive either sevoflurane or a standard sedative (midazolam). The main goal was to see if sevoflurane could improve gas exchange in the lungs.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sevoflurane
What this could lead to
If it works, this could point toward a new sedation method that also helps ARDS patients breathe better and reduces lung inflammation.
What could go wrong
This is a small, early-phase study with only 50 participants, so results may not apply broadly. The drug is already used for sedation, but its specific benefit for ARDS is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

50 people

The number who actually took part.

Start date

Apr 2014

Finished

Mar 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with criteria for moderate to severe ARDS since less than 24 hours ( * Informed consent Exclusion Criteria: * Suspected or proven intracranial hypertension * Midazolam, sevoflurane or cisatracurium allergy * Medical history of malignant hyperthermia * Severe liver failure * Chemotherapy treatment in the last month * Severe neutropenia (\< 0.5 G/l)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute respiratory distress syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome adult acute respiratory distress syndrome Inflammation Lung Injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute respiratory distress syndrome

Contacts and locations

Locations

  • CHU Clermont-Ferrand

    Clermont-Ferrand, 63003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.